CHARITY COMMISSION
FOR ENGLAND AND WALES
Trustees, Annual Report for the period
From
1 January 2020
31 Decombor 2020
Charlty name: Arrhythmog•nlc Cardlomyopathy Trust
Charity rnglstration number: 1176790
Objectives and Activities
Summary of the purposes of
the charity 45 sol out In
governing documertt
P*¥117
TO PROMOTE AND PROTECT GOOD
HEALTH FOR THE PUBLIC BENEFIT.
RELATING TO INHERITED HEART
CONDITIONS AND IN PARTICULAR
ARRYTHMOGENIC CAADIOMYOPATHY
BY FUNDING RESEARCH PROJECTS,
SUCH PROJECTS CAN BE
DIAGNOSTIC, CURATIVE.
THERAPEUTIC OR PALLIATIVE IN
NATURE AND TO ENSURE THE
PUBLICATION OF THE USEFUL
RESULTS OF SUCH FIESEARCH.
Summary of the main
activities In relation lo those
purposes lor Ihe public
benefit. In partlCLtlaf. the
activities. proieds or
serviees Identified in the
accounts
P¥41 17v
Further lundraising. Funding call and
tender process lor lirst grant. with shortlisl
ol loui ap￿iCatIonS. Review ol applicats'on
in eoniunction with Cafdiomyopalhy UK
and rewesentalives from lour principal UK
NHS Tnjsls. Final decision TeaC￿d on
lunding research project and
Commer￿eMent ol legal agreement.
This guKlance has been noted by the
truste9$ of Ihe charty.
Slalemenl confirming
whether the Irustees have
had regard lo the guidance
issued by the Chaiity
Commission on public
benefit

Achievements and Performance
During the year, the chartty has
successlully raised a further £20,303 to
support its objectives of funding medical
research projects locussed on
Arrhylhmogenic Cardiomyopaihy, a heart
muscle disease that affects young people.
Summary oflhe main
achievements ol the chanly,
Idenlifying the difference the
charity s work has made to
Ihe circumstances of Ils
beneficianes and any wider
benefits 10 50aety as
whole
Pw•120
This means that the Charity has raised
almost £l1)0,000 lo achieve ils objectives.
In 2018, Ihe charity slated its aim ol
linalising a projed lor support in year 3 01
operaDon120201. This aim was achieved
through the charity's first lunding call, and
successful interview process. Four
applicabons weie $horUisled lor inlervi8W,
with a final agreement reached with tho
successful applicant in November 2020.
The project'Disease Siralificalion in
Arrhythmogenic Cardiomyopathy, ￿11 be
undertaken by UCL, funded by ACT. and
will commence in 2021.

Financial Review
Review ol the chanty's
financial position al the erKI
of the period
Pw•121
The charity is on course lo achieve rts
objectives of making a research grant In
year 3120201 The charity holds only cash
deposits, with no debt
Reserves will be held on an ongoing basis
until a research project Is successftjlly
lunded
Statement explaining the
policy for holding ￿SerVeS
51aling why they are held
Amount of reserves held
Reasons lor hol(Jing zero
reserves
r• I IZ
',P*rn122
£98,303
,Pw•122
nla
Delails ol fund materially In
deficit
PmlZ4
I nla
Explanatson of any
uncertainties about the
charity ¢onbnuing as a going
concem
No concems

Striicliiro. Govorii*nc• aii(l Maiiagomonl
CIO yov•ininu docum•nl
cio
Tiu•l••• iFwnl•d by i••olulion ol exi•bn
*i)v pni•on ui iK)dy •nlill•d
lo aiiwiinl on• L)r nioi•
Rof•r•nc• and Admlnl8lrallve detall•
Chjfily n•m•
Olh•r n•m• Iho ch•rily
RfrgI•i•i￿ ch•rily numb•r
Ch•nly'• pnneip•l •ddr••i
Arihythm¢)g•nic card￿my0p￿1hY Tru•l
ACT
1170790
97 Ro￿bank. HolyF47rt Ro4d. London SM 6U

Names of the charity trustees who manage the ch#rity
TnMts• n•m•
DatH acted 11 not lor
whol• yvr
Nam• of per•oD lor body)
•ntitl•d to lppolnt tru•tse
James Minch
Trustee
Kale Minch
Trustee
Rachel Bailey
Trustee
10
11
12
13
14
15
16
17
18
19
20
Corporate Iruslees- names ol the diTettors al the dale the report was approved
Dlr•Gtor Mm•
Name of trustees holding lille lo propety belonging lo the charity
Tru•tre name
Oats• *Cknd rf notfor whol• yur

Funds held as custodian trustees on behalf of others
i Descnplion ol the assets
nla
held In this capacrty
i Name and obiects of the
chanty on whose behalf the
assets are held and how this I
falls within ihe custodian
' charty's objecis
'nla
Details of arrangements for I nla
sale Custody and
sggregatson ol such assels
I from the chanty's ¢Nn assets
Exemptions from disclosure
Reason for non-disdosure of key personnel dtlaily
Other optional Information

Declaratlon3
Th• tru•t••• d•¢l•r• thal th•y h•v• •ppmv•d th• tru•lw•' rnporl •bov•.
Slgr*•d on b•half of th• ¢ty•rlty'• truit•••
Full n•iiid•l iAMi3
il-. HSL £4LI.C
Po•liion l•g
SKr•tsry, Ch•lr. •tcl . IRM%TE[
rcuSTEE
D•1•
Iq

||**Arrhythmogenic Cardiomyopathy Trust**|**Arrhythmogenic Cardiomyopathy Trust**|**Arrhythmogenic Cardiomyopathy Trust**|**Arrhythmogenic Cardiomyopathy Trust**|**Arrhythmogenic Cardiomyopathy Trust**|**No(if any)**|**No(if any)**||
|---|---|---|---|---|---|---|---|---|
||||||||||
||**Receipts andpayments accounts**||||||||
||**For the period**<br>**from**||01/01/2020||**To**||31/12/2020||
||||||||||
||||||||||
|**Section A Receipts and payments**|||||||||
||**Unrestricted**<br>**funds**||**Restricted funds**||**Endowment**<br>**funds**||**Total funds**||
||**to the nearest      £**||**to the nearest £**||**to the nearest £**||**to the nearest £**||
|**A1 Receipts**|||||||||
|Income|**20,303**||**-**||**-**||**20,303**||
||**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
|**_Sub total_**_(Gross income for AR) _|<br>**20,303**||**-**||**-**||**20,303**||
||||||||||
|**A2 Asset and investment sales,**<br>**(see table).**|||||||||
||**- 0**||**- 0**||**- 0**||**-**||
||**- 0**||**- 0**||**- 0**||**-**||
|**_Sub total _**|<br>**- 0**||**- 0**||**- 0**||**-**||
||||||||||
|**_Total receipts_ **|<br>**20,303**||**- 0**||**- 0**||**20,303**||
||||||||||
|**A3 Payments**|||||||||
|Expenses|**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
||**- 0**||**-**||**-**||**-**||
|**_Sub total_ **|<br>**- 0**||**-**||**-**||**-**||
||||||||||
|**A4 Asset and investment**<br>**purchases,(see table)**|||||||||
||**- 0**||**- 0**||**- 0**||**-**||
||**- 0**||**- 0**||**- 0**||**-**||
|**_Sub total_ **|<br>**-0**||**-0**||**-0**||**-**||
||||||||||
|**_Totalpayments_ **|<br>**- 0**||**- 0**||**- 0**||**-**||
||||||||||
|**_Net of receipts/(payments)_ **|<br>**20,303**||**-**||**-**||**20,303**||
|**A5 Transfers between funds**|**- 0**||**-**||**-**||**-**||
|**A6 Cash funds lastyear end**|**- 0**||**-**||**-**||**-**||
|**_Cash funds thisyear end_ **|<br>**20,303**||**-**||**-**||**20,303**||
||||||||||
||||||||||
|**Section B Statement of assets and liabilities at the end of the period**|||||||||
|**Categories**|**Details**||||**Unrestricted**<br>**funds**||**Restricted funds**||
||||||**to nearest £**||**to nearest £**||
|**B1 Cash funds**|||||**87,493**||**-**||
||||||**-**||**-**||



CCXX R1 accounts (SS) 

31/10/2020 

1 



||||||**-**||**-**||
|---|---|---|---|---|---|---|---|---|
||**_Total cash funds_**||||**87,493**||**-**||
||(agree balances with receipts and payments<br>account(s))||||Agreement Error||||
||||||**Unrestricted**<br>**funds**||**Restricted funds**||
||**Details**||||**to nearest £**||**to nearest £**||
|**B2 Other monetary assets**|||||**-**||**-**||
||||||**-**||**-**||
||||||**-**||**-**||
||||||**-**||**-**||
||||||**-**||**-**||
||||||**-**||**-**||
||||||||||
||**Details**||||**Fund to which asset**<br>**belongs**||**Cost (optional)**||
|**B3 Investment assets**|||||||**-**||
||||||||**-**||
||||||||**-**||
||||||||**-**||
||||||||**-**||
||||||||||
||**Details**||||**Fund to which asset**<br>**belongs**||**Cost (optional)**||
|**B4 Assets retained for the**<br>**charity’s own use**|||||||**-**||
||||||||**-**||
||||||||**-**||
||||||||**-**||
||||||||**-**||
||||||||**-**||
||||||||**-**||
||||||||**-**||
||||||||**-**||
||||||||||
||**Details**||||**Fund to which**<br>**liability relates**||**Amount due**<br>**(optional)**||
|**B5 Liabilities**|||||||**-**||
||||||||**-**||
||||||||**-**||
||||||||**-**||
||||||||**-**||
||||||||||
|Signed by one or two trustees on behalf<br>of all the trustees|Signature||||Print Name||||
||||||||||
||||||||||



CCXX R2 accounts (SS) 

31/10/2020 

2 



**CC16a Last year to the nearest £ - - - - - - - - - - 0 - 0 - 0 - - - - - - - - - - - 0 - 0 - - - - Endowment funds to nearest £ - -** 

CCXX R3 accounts (SS) 

31/10/2020 

3 



**-** OK **Endowment funds to nearest £ - - - - - - Current value (optional) - - - - - Current value (optional) - - - - - - - - - When due (optional)** 


Date of approval 


CCXX R4 accounts (SS) 

31/10/2020 

4